Procaps GroupPROC
PROC
About: Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.
Employees: 5,500
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0.01% less ownership
Funds ownership: 0.16% [Q2] → 0.15% (-0.01%) [Q3]
19% less capital invested
Capital invested by funds: $453K [Q2] → $367K (-$85.7K) [Q3]
29% less funds holding
Funds holding: 7 [Q2] → 5 (-2) [Q3]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Research analyst outlook
We haven’t received any recent analyst ratings for PROC.
Financial journalist opinion
Neutral
GlobeNewsWire
5 days ago
Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates
MIAMI and BARRANQUILLA, Colombia, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced significant outcomes from its recent Shareholders Meeting and subsequent Board of Directors meeting. These include changes to the Board composition, restructuring of Board committees, and updates to its executive leadership team.
Neutral
GlobeNewsWire
3 weeks ago
Procaps Group Announces Financing, Shareholders Agreement and Board Updates
MIAMI and BARRANQUILLA, Colombia , Dec. 03, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced the successful execution of key strategic transactions and governance updates aimed at strengthening its financial position and supporting long-term growth objectives.
Neutral
GlobeNewsWire
1 month ago
Procaps Receives Nasdaq Listing Determination; To Request Hearing and Further Stay Pending Hearing
MIAMI and BARRANQUILLA, Colombia, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), announced today that, on November 13, 2024, the Company received formal notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company's failure to timely file the Form 20-F for the fiscal year ended December 31, 2023 (the “Form 20-F”) with the U.S. Securities and Exchange Commission (the “SEC”), the Company no longer satisfied Nasdaq Listing Rule 5250(c)(1) (the “Filing Rule”) and its securities are therefore subject to suspension and delisting unless the Company timely requests a hearing before and a further stay of any suspension action at least pending the ultimate conclusion of the hearings process from the Nasdaq Hearings Panel (the “Panel”).
Neutral
GlobeNewsWire
2 months ago
Procaps Issues Shareholder Letter Update
MIAMI and BARRANQUILLA, Colombia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services, today issued the below letter to shareholders from José Antonio Vieira, CEO of Procaps, providing critical updates on the Company's ongoing independent investigation, financial restatement, governance enhancements, and commitment to long-term stability.
Neutral
GlobeNewsWire
3 months ago
Procaps Issues Shareholder Letter Update
MIAMI and BARRANQUILLA, Colombia, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services, today issued the below letter to shareholders from José Antonio Vieira, CEO of Procaps, with updates on the Company's restructuring and strategic plan projects.
Neutral
GlobeNewsWire
3 months ago
Procaps Issues Shareholder Letter
MIAMI and BARRANQUILLA, Colombia, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today issued the below letter to shareholders from José Antonio Vieira, CEO of Procaps, addressing the current state of the business and outlining key strategic priorities for the Company.
Positive
InvestorPlace
5 months ago
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price.
Neutral
Business Wire
5 months ago
Procaps Group Announces New Chairman
MIAMI & BARRANQUILLA, Columbia--(BUSINESS WIRE)--Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced that Mr. Ruben Minski has resigned from his role as Executive Chairman of the Board, effective June 30th. Mr. Minski will continue to serve as a member of the Board of Directors. Reflecting on his decision, Ruben stated: “This month marked six months since Jose Antonio Vieira assumed the role of CEO of.
Neutral
Business Wire
7 months ago
Procaps Group Receives Nasdaq Notice Related to Late Filing of its Form 20-F
MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Receives Nasdaq Notice Related to Late Filing of its Form 20-F.
Neutral
Business Wire
7 months ago
Procaps Group Delays Filing of Annual Report on Form 20-F
MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Delays Filing of Annual Report on Form 20-F.
Charts implemented using Lightweight Charts™